Glucagon-Like Peptide-1 Analogues Market to Surpass USD 299.08 Billion by 2033, Fueled by the Weight Management and Diabetes Revolution | DataM Intelligence

Market Dynamics: The Dual Impact of Diabetes and Obesity Epidemics Market Dynamics: The Dual Impact of Diabetes and Obesity Epidemics The GLP-1 analogues market is being reshaped by intersecting public health trends- the global rise in obesityand theincreasing prevalence of type 2 diabetes. According to DataM Intelligence, over1 billion people worldwideare now classified as obese, while diabetes affectsover 540 million adults globally, intensifying the need for multi-target...

Market Dynamics: The Dual Impact of Diabetes and Obesity Epidemics

The GLP-1 analogues market is being reshaped by intersecting public health trends-the global rise in obesity and the increasing prevalence of type 2 diabetes. According to DataM Intelligence, over 1 billion people worldwide are now classified as obese, while diabetes affects over 540 million adults globally, intensifying the need for multi-target therapeutic options.

Key Market Drivers Include:

Download PDF Brochure: https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market 

Browse in-depth TOC on 'GLP-1 Analogues Market'
79 – Tables
73 – Figures
215 – Pages

Market Segmentation Analysis

The global GLP-1 analogues market is segmented By Product, By Type, By Route of Administration, By Application, and By Distribution Channel.

By Product

The semaglutide-based formulations (marketed under Ozempic, Wegovy, and Rybelsus) dominated the product landscape in 2024, accounting for over 45% of global market share, equivalent to approximately USD 28 billion. These drugs have set new standards for efficacy, with average weight loss of 15–20% observed in clinical trials.

Liraglutide-based products (Saxenda, Victoza) represented the second-largest share, though their growth has plateaued due to next-generation replacements. Emerging competitors like tirzepatide (Mounjaro)-a dual GLP-1/GIP receptor agonist-are projected to capture nearly 25% of the market by 2027, driven by superior weight loss efficacy and growing regulatory approvals.

By Type

Based on molecular structure and modification, the market is classified into short-acting and long-acting GLP-1 analogues. Long-acting analogues, such as semaglutide and dulaglutide, dominate with approximately 70% market share in 2024 due to lower injection frequency and sustained glycemic control. Short-acting analogues like exenatide retain niche use for postprandial glucose regulation.

By Route of Administration

Injectable formulations continue to account for nearly 85% of global sales (USD 53 billion in 2024). However, oral formulations-led by Rybelsus (oral semaglutide)-are expected to expand rapidly, growing at over 22% CAGR through 2033. The convenience of daily oral dosing is anticipated to attract a new segment of non-insulin-dependent diabetic patients and weight management consumers.

By Application

While type 2 diabetes remains the dominant indication, representing 60% of total market demand, the obesity management segment is witnessing exponential growth, projected to rise from USD 18 billion in 2024 to over USD 150 billion by 2033. This transition reflects the shifting therapeutic focus of GLP-1 analogues from glucose regulation to holistic metabolic management.

Emerging applications include cardiovascular risk reduction and non-alcoholic steatohepatitis (NASH), both under active clinical evaluation by key industry leaders.

By Distribution Channel

In 2024, hospital and specialty clinics represented nearly 50% of global GLP-1 analogue prescriptions, while retail and online pharmacies accounted for the remaining share. The online channel is expanding rapidly due to growing direct-to-consumer telemedicine platforms offering prescription weight-loss programs.

Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market 

Regional Insights: United States and Japan Lead Market Expansion

United States Market

The United States dominates the global GLP-1 analogues market, accounting for nearly 65% of global sales, equivalent to USD 40.8 billion in 2024. The U.S. has witnessed explosive adoption due to the unprecedented popularity of weight-loss drugs such as Wegovy and Mounjaro, coupled with favorable reimbursement policies and expanded production capacity by leading pharmaceutical firms.

Recent U.S. market developments (2025):

As a result, U.S. prescriptions for GLP-1 analogues surged by over 160% year-over-year between 2023 and 2024, marking one of the fastest adoption cycles in pharmaceutical history.

Japan Market

Japan is emerging as a major growth frontier for GLP-1 therapies, particularly driven by a rise in obesity rates among adults aged 35–60. The Japanese GLP-1 market reached USD 2.1 billion in 2024, representing approximately 3.3% of global share, and is projected to exceed USD 8.7 billion by 2033.

Recent updates include:

Competitive Landscape

The GLP-1 analogues market is dominated by a few key players, with Eli Lilly and Novo Nordisk together holding over 80% of global revenue as of 2024. However, new entrants and regional biopharma companies are actively developing differentiated delivery systems and combination therapies to capture emerging niches.

Key Players:
Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Boehringer Ingelheim, Glenmark Pharmaceuticals Ltd., Hanmi Pharm Co., Ltd., Amgen Inc., Gmax Biopharm, and Sciwind Biosciences Co., Ltd.

Revenue Highlights (FY2024):

Together, these companies represent the backbone of the rapidly expanding GLP-1 ecosystem, supported by over 150 ongoing global clinical trials targeting diabetes, obesity, and metabolic syndrome.

Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market 

Recent Industry Developments:

Market Outlook and Opportunities

DataM Intelligence projects that the GLP-1 analogues market will continue its meteoric rise as multi-indication use expands beyond diabetes into obesity, NASH, and cardiovascular health. The industry's next phase will be defined by innovations in oral delivery systems, peptide stability, and dual/triple receptor agonists.

Key projections:

Conclusion

The Glucagon-like Peptide-1 (GLP-1) Analogues Market stands at the epicenter of the global pharmaceutical revolution, redefining chronic disease management and reshaping the future of metabolic care.

According to DataM Intelligence, with a market poised to surge from USD 62.81 billion in 2024 to USD 299.08 billion by 2033, the next decade will witness continued innovation, patient access expansion, and strategic collaborations among industry leaders. As GLP-1 therapies evolve from injectable to oral and combination formats, they are set to transform healthcare outcomes for millions battling diabetes, obesity, and associated metabolic disorders worldwide.

Related Report:

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Sai Kiran
DataM Intelligence 4 Market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866 
Email: [email protected] 

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/glucagon-like-peptide-1-analogues-market-to-surpass-usd-299-08-billion-by-2033--fueled-by-the-weight-management-and-diabetes-revolution--datam-intelligence-302596816.html